<Version>
  <xmlSource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlSource>
  <Section SecID="390" OrdBy="100" Name="General">
    <Field FieldID="161" OrdBy="105" ID="391" Name="Guideline Title" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;Best evidence statement (BESt). Venous thromboembolism (VTE) prophylaxis in children and adolescents.&lt;/div&gt;" />
    </Field>
    <Field FieldID="97" OrdBy="110" ID="392" Name="Bibliographic Source(s)" Type="citation">
      <FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Cincinnati Children's Hospital Medical Center. Best evidence statement (BESt). Venous thromboembolism (VTE) prophylaxis in children and adolescents. Cincinnati (OH): Cincinnati Children's Hospital Medical Center; 2014 Feb 18. 14 p.  [40 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" />
    </Field>
    <Field FieldID="120" OrdBy="115" ID="393" Name="Guideline Status" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
  </Section>
  <Section SecID="420" OrdBy="300" Name="Recommendations">
    <Field FieldID="151" OrdBy="310" ID="421" Name="Major Recommendations" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The strength of the recommendation (strongly recommended, recommended, or no recommendation) and the quality of the evidence (1aâ5b) are defined at the end of the &quot;Major Recommendations&quot; field.&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;It is recommended that patients age 10 to 17 years who are expected to have a surgical procedure lasting at least 60 minutes be started at induction of anesthesia on a sequential compression device (SCD), for prophylaxis of venous thromboembolism (VTE), unless there are contraindications to mechanical prophylaxis (Schwenk et al., 1998 [2b]; Local Consensus, 2014 [5]; Coleridge-Smith, Hasty, &amp;amp; Scurr, 1990 [5]; Branchford et al., &quot;Clinical,&quot; 2012 [5b]). See Table 1 in the original guideline document. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;It is recommended that all patients age 10 to 17 years be assessed for VTE risk factors (see Table 2 in the original guideline document) and, based on that assessment, assigned to a risk category (low, moderate or high) (see Table 3 in the original guideline document):&#xD;&#xA;    &lt;ol style=&quot;list-style-type: lower-alpha;&quot;&gt;&#xD;&#xA;        &lt;li&gt;At the time of inpatient admission, and &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Reassessed at 48 to 72 hours of hospitalization&#xD;&#xA;        &lt;p&gt;(Branchford et al., &quot;Risk,&quot; 2012 [4a]; Sharathkumar et al., 2012 [4a]; Local Consensus, 2014 [5]). See the Algorithm in the original guideline document.&lt;/p&gt;&#xD;&#xA;        &lt;/li&gt;&#xD;&#xA;    &lt;/ol&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;3&quot;&gt;&#xD;&#xA;    &lt;li&gt;It is recommended that VTE prophylaxis be administered based on risk category (see Table 4 in the original guideline document), as soon as feasible but within 24 hours of assessment, unless there are contraindications (see Table 1 and Table 5 in the original guideline document). See the Algorithm in the original guideline document.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Note&lt;/strong&gt;: Examples of risk factor mitigation strategies are: discontinuing peripherally-inserted central catheter (PICC) lines as soon as possible, treating infections, and avoiding estrogen therapy.&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;It is recommended, if planning to initiate pharmacologic prophylaxis:&#xD;&#xA;    &lt;ol style=&quot;list-style-type: lower-alpha;&quot;&gt;&#xD;&#xA;        &lt;li&gt;In surgical patients seek surgical input regarding bleeding risk, prior to initiation. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Obtain hematology consultation when considering alternative pharmacologic agents&#xD;&#xA;        &lt;p&gt;(Alhazzani et al., 2013 [1a]; Barrera et al., 2013 [1a]; Handoll et al., 2002 [1a]; Bidlingmaier et al., 2011 [1b]; Kakkos et al., 2011 [1b]; Stem et al., 2013 [3b]; Local Consensus, 2014 [5]).&lt;/p&gt;&#xD;&#xA;        &lt;/li&gt;&#xD;&#xA;    &lt;/ol&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Definitions&lt;/strong&gt;&lt;/span&gt;:&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Table of Evidence Levels&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table of Evidence Levels&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot; scope=&quot;col&quot;&gt;Quality Level&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot; scope=&quot;col&quot;&gt;Definition&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; scope=&quot;row&quot;&gt;1a&amp;dagger; or 1b&amp;dagger;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Systematic review, meta-analysis, or meta-synthesis of multiple studies&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; scope=&quot;row&quot;&gt;2a or 2b&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Best study design for domain&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; scope=&quot;row&quot;&gt;3a or 3b&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Fair study design for domain&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; scope=&quot;row&quot;&gt;4a or 4b&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Weak study design for domain&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; scope=&quot;row&quot;&gt;5a or 5b&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;General review, expert opinion, case report, consensus report, or guideline&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; scope=&quot;row&quot;&gt;5&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Local Consensus&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&amp;dagger;a = good quality study; b = lesser quality study.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Table of Language and Definitions for Recommendation Strength&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table of Recommendation Strength&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot; scope=&quot;col&quot;&gt;Strength&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot; scope=&quot;col&quot;&gt;Definition&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; scope=&quot;row&quot;&gt;It is strongly recommended that&amp;hellip;&lt;br /&gt;&#xD;&#xA;            &lt;br /&gt;&#xD;&#xA;            It is strongly recommended that&amp;hellip; not&amp;hellip; &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;When the dimensions for judging the strength of the evidence are applied, there is high support that benefits clearly outweigh risks and burdens (or vice-versa for negative recommendations).&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; scope=&quot;row&quot;&gt;It is recommended that&amp;hellip; &lt;br /&gt;&#xD;&#xA;            &lt;br /&gt;&#xD;&#xA;            It is recommended that&amp;hellip; not&amp;hellip; &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;When the dimensions for judging the strength of the evidence are applied, there is moderate support that benefits are closely balanced with risks and burdens.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; colspan=&quot;2&quot; scope=&quot;row&quot;&gt;There is insufficient evidence and a lack of consensus to make a recommendation&amp;hellip; &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;strong&gt;Note&lt;/strong&gt;: See the original guideline document for the dimensions used for judging the strength of the recommendation.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="138" OrdBy="330" ID="423" Name="Clinical Algorithm(s)" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;An algorithm titled &quot;Risk Category Assessment and Prophylaxis for Venous Thromboembolism&quot; is provided in the original guideline document.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
  </Section>
  <Section SecID="396" OrdBy="400" Name="Scope">
    <Field FieldID="140" OrdBy="405" ID="397" Name="Disease/Condition(s)" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Venous thromboembolism (VTE)&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="103" OrdBy="410" ID="398" Name="Guideline Category" Type="picklist-many">
      <FieldValue Value="Management" />
      <FieldValue Value="Risk Assessment" />
      <FieldValue Value="Treatment" />
    </Field>
    <Field FieldID="113" OrdBy="415" ID="399" Name="Clinical Specialty" Type="picklist-many">
      <FieldValue Value="Anesthesiology" />
      <FieldValue Value="Internal Medicine" />
      <FieldValue Value="Pediatrics" />
      <FieldValue Value="Surgery" />
    </Field>
    <Field FieldID="114" OrdBy="420" ID="400" Name="Intended Users" Type="picklist-many">
      <FieldValue Value="Hospitals" />
      <FieldValue Value="Physicians" />
    </Field>
    <Field FieldID="129" OrdBy="425" ID="401" Name="Guideline Objective(s)" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;To evaluate, among hospitalized children, if risk assessment and stratified venous thromboembolism (VTE) prophylaxis compared to no prophylaxis reduces VTE occurrence without an increase in significant adverse effects&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="132" OrdBy="430" ID="402" Name="Target Population" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Hospitalized patients age 10 to 17 years (up to the 18th birthday)&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;strong&gt;Note&lt;/strong&gt;: Patients with current venous thromboembolism (VTE) are excluded from this guideline.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="133" OrdBy="435" ID="403" Name="Interventions and Practices Considered" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Risk assessment and stratified venous thromboembolism (VTE) prophylaxis&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="134" OrdBy="440" ID="404" Name="Major Outcomes Considered" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Reduced venous thromboembolism (VTE) occurrence without an increase in significant adverse effects&lt;/p&gt;&lt;/div&gt;" />
    </Field>
  </Section>
  <Section SecID="405" OrdBy="500" Name="Methodology">
    <Field FieldID="109" OrdBy="505" ID="406" Name="Methods Used to Collect/Select the Evidence" Type="picklist-many">
      <FieldValue Value="Hand-searches of Published Literature (Primary Sources)" />
      <FieldValue Value="Hand-searches of Published Literature (Secondary Sources)" />
      <FieldValue Value="Searches of Electronic Databases" />
    </Field>
    <Field FieldID="135" OrdBy="510" ID="407" Name="Description of Methods Used to Collect/Select the Evidence" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Search Strategies &lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Iterative searches were conducted in the course of the development of this document.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Search 1: Venous Thromboembolism (VTE) Prophylaxis in Pediatric Trauma and Orthopaedic Patients&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;Databases&lt;/strong&gt;: MEDLINE, Cochrane Database of Systematic Reviews (CDSR), CINAHL &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;Terms&lt;/strong&gt;: Various terms for VTE (VTE, DVT, PE, thrombosis, venous thrombosis, thromboembolism, deep vein thrombosis, pulmonary embolism) AND various terms for trauma or orthopaedic surgery (trauma, wounds, injuries, orthopedic) AND various terms for VTE prophylaxis (enoxaparin, heparin, anticoagulants fibrinolytic agents, prophylaxis combined with thrombus or embolus) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;Filters&lt;/strong&gt;: Publication dates 2000 to present; pediatric studies only; English language &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;Date search was conducted&lt;/strong&gt;: November 14, 2012; update of search conducted January 13, 2014 &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Search 2: Adverse Events with VTE Prophylaxis in Hospitalized Children&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;Databases&lt;/strong&gt;: MEDLINE, Cochrane, CINAHL, Scopus, EBMR &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;Terms&lt;/strong&gt;: Various terms for VTE prophylaxis (enoxaparin, heparin, anticoagulants fibrinolytic agents, prophylaxis combined with thrombus or embolus) AND various terms for adverse events (hemorrhage, bleeding, risk of bleeding, adverse effect, adverse event) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;Filters&lt;/strong&gt;: Publication dates 2000 to present; pediatric studies only; English language &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;Date search was conducted&lt;/strong&gt;: January 24, 2013; update of search conducted January 13, 2014 &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Search 3: Mechanical Prophylaxis of VTE&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;Databases&lt;/strong&gt;: MEDLINE, Scopus, CINAHL, CDSR &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;Terms&lt;/strong&gt;: Various terms for VTE (VTE, DVT, PE, thrombosis, venous thrombosis, thromboembolism, deep vein thrombosis, pulmonary embolism) AND various terms for mechanical prophylaxis (intermittent compression device, mechanical prophylaxis, sequential compression device, foot pump, pneumatic compression, graduated compression stocking, TED stockings, elastic compression stockings) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;Filters&lt;/strong&gt;: No limits on patient age or on publication dates; English language &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;Date search was conducted&lt;/strong&gt;: February 26, 2013; update of search conducted January 13, 2014 &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Search 4: Definitions of Immobilization&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;Database&lt;/strong&gt;: MEDLINE &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;Terms&lt;/strong&gt;: Various terms for VTE (VTE, DVT, PE, thrombosis, venous thrombosis, thromboembolism, deep vein thrombosis, pulmonary embolism) AND various terms for immobilization (immobility, bed rest, bedridden, confined to bed) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;Filters&lt;/strong&gt;: No limits on publication dates; pediatric studies or meta-analyses of adult studies; English language &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;Date search was conducted&lt;/strong&gt;: May 2, 2013; update of search conducted January 13, 2014 &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;In addition, articles identified by members of the team and relevant articles from reference lists were considered.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="136" OrdBy="515" ID="408" Name="Number of Source Documents" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="115" OrdBy="520" ID="409" Name="Methods Used to Assess the Quality and Strength of the Evidence" Type="picklist-choice">
      <FieldValue Value="Weighting According to a Rating Scheme (Scheme Given)" />
    </Field>
    <Field FieldID="149" OrdBy="525" ID="410" Name="Rating Scheme for the Strength of the Evidence" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Table of Evidence Levels&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table of Evidence Levels&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot; scope=&quot;col&quot;&gt;Quality Level&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot; scope=&quot;col&quot;&gt;Definition&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; scope=&quot;row&quot;&gt;1a&amp;dagger; or 1b&amp;dagger;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Systematic review, meta-analysis, or meta-synthesis of multiple studies&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; scope=&quot;row&quot;&gt;2a or 2b&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Best study design for domain&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; scope=&quot;row&quot;&gt;3a or 3b&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Fair study design for domain&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; scope=&quot;row&quot;&gt;4a or 4b&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Weak study design for domain&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; scope=&quot;row&quot;&gt;5a or 5b&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;General review, expert opinion, case report, consensus report, or guideline&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; scope=&quot;row&quot;&gt;5&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Local Consensus&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&amp;dagger;a = good quality study; b = lesser quality study.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="116" OrdBy="530" ID="411" Name="Methods Used to Analyze the Evidence" Type="picklist-many">
      <FieldValue Value="Review of Published Meta-Analyses" />
      <FieldValue Value="Systematic Review" />
    </Field>
    <Field FieldID="150" OrdBy="535" ID="412" Name="Description of the Methods Used to Analyze the Evidence" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="112" OrdBy="540" ID="413" Name="Methods Used to Formulate the Recommendations" Type="picklist-choice">
      <FieldValue Value="Expert Consensus" />
    </Field>
    <Field FieldID="145" OrdBy="545" ID="414" Name="Description of Methods Used to Formulate the Recommendations" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="146" OrdBy="550" ID="415" Name="Rating Scheme for the Strength of the Recommendations" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Table of Language and Definitions for Recommendation Strength&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table of Recommendation Strength&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot; scope=&quot;col&quot;&gt;Strength&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot; scope=&quot;col&quot;&gt;Definition&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; scope=&quot;row&quot;&gt;It is strongly recommended that&amp;hellip;&lt;br /&gt;&#xD;&#xA;            &lt;br /&gt;&#xD;&#xA;            It is strongly recommended that&amp;hellip; not&amp;hellip; &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;When the dimensions for judging the strength of the evidence are applied, there is high support that benefits clearly outweigh risks and burdens (or vice-versa for negative recommendations).&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; scope=&quot;row&quot;&gt;It is recommended that&amp;hellip; &lt;br /&gt;&#xD;&#xA;            &lt;br /&gt;&#xD;&#xA;            It is recommended that&amp;hellip; not&amp;hellip; &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;When the dimensions for judging the strength of the evidence are applied, there is moderate support that benefits are closely balanced with risks and burdens.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; colspan=&quot;2&quot; scope=&quot;row&quot;&gt;There is insufficient evidence and a lack of consensus to make a recommendation&amp;hellip; &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;strong&gt;Note&lt;/strong&gt;: See the original guideline document for the dimensions used for judging the strength of the recommendation.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="148" OrdBy="565" ID="417" Name="Cost Analysis" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;A formal cost analysis was not performed and published cost analyses were not reviewed.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="104" OrdBy="570" ID="418" Name="Method of Guideline Validation" Type="picklist-choice">
      <FieldValue Value="Peer Review" />
    </Field>
    <Field FieldID="130" OrdBy="575" ID="419" Name="Description of Method of Guideline Validation" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This Best Evidence Statement (BESt) has been reviewed against quality criteria by two independent reviewers from the Cincinnati Children's Hospital Medical Center (CCHMC) Evidence Collaboration.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
  </Section>
  <Section SecID="424" OrdBy="600" Name="Evidence Supporting the Recommendations">
    <Field FieldID="98" OrdBy="605" ID="425" Name="References Supporting the Recommendations" Type="citation">
      <FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Alhazzani W, Lim W, Jaeschke RZ, Murad MH, Cade J, Cook DJ. Heparin thromboprophylaxis in medical-surgical critically ill patients: a systematic review and meta-analysis of randomized trials. Crit Care Med. 2013 Sep;41(9):2088-98. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23782973&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" />
      <FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Barrera LM, Perel P, Ker K, Cirocchi R, Farinella E, Morales Uribe CH. Thromboprophylaxis for trauma patients. Cochrane Database Syst Rev. 2013;3:CD008303. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23543562&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" />
      <FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Bidlingmaier C, Kenet G, Kurnik K, Mathew P, Manner D, Mitchell L, KrÃ¼mpel A, Nowak-GÃ¶ttl U. Safety and efficacy of low molecular weight heparins in children: a systematic review of the literature and meta-analysis of single-arm studies. Semin Thromb Hemost. 2011 Oct;37(7):814-25. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22187405&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" />
      <FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Branchford B, Wang M, Wathen B, Ranade D, Neiman J, Coughlin R, Pickard D, Children's Hospital of Colorado. Clinical care guideline: VTE prophylaxis 2012 (unpublished document). 2012. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" />
      <FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Branchford BR, Mourani P, Bajaj L, Manco-Johnson M, Wang M, Goldenberg NA. Risk factors for in-hospital venous thromboembolism in children: a case-control study employing diagnostic validation. Haematologica. 2012 Apr;97(4):509-15. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22133768&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" />
      <FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Coleridge-Smith PD, Hasty JH, Scurr JH. Venous stasis and vein lumen changes during surgery. Br J Surg. 1990 Sep;77(9):1055-9. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2207573&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" />
      <FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Handoll HH, Farrar MJ, McBirnie J, Tytherleigh-Strong G, Milne AA, Gillespie WJ. Heparin, low molecular weight heparin and physical methods for preventing deep vein thrombosis and pulmonary embolism following surgery for hip fractures. Cochrane Database Syst Rev. 2002;(4):CD000305. [68 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12519540&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" />
      <FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Kakkos SK, Caprini JA, Geroulakos G, Nicolaides AN, Stansby GP, Tsolakis IA, Reddy DJ. Can combined (mechanical and pharmacological) modalities prevent fatal VTE?. Int Angiol. 2011 Apr;30(2):115-22. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21427647&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" />
      <FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Schwenk W, BÃ¶hm B, FÃ¼gener A, MÃ¼ller JM. Intermittent pneumatic sequential compression (ISC) of the lower extremities prevents venous stasis during laparoscopic cholecystectomy. A prospective randomized study. Surg Endosc. 1998 Jan;12(1):7-11. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9419295&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" />
      <FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Sharathkumar AA, Mahajerin A, Heidt L, Doerfer K, Heiny M, Vik T, Fallon R, Rademaker A. Risk-prediction tool for identifying hospitalized children with a predisposition for development of venous thromboembolism: Peds-Clot clinical Decision Rule. J Thromb Haemost. 2012 Jul;10(7):1326-34. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22583578&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" />
      <FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Stem J, Christensen A, Davis D, Raffini L. Safety of prophylactic anticoagulation at a pediatric hospital. J Pediatr Hematol Oncol. 2013 Oct;35(7):e287-91. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23774158&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" />
    </Field>
    <Field FieldID="139" OrdBy="610" ID="426" Name="Type of Evidence Supporting the Recommendations" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The type of supporting evidence is identified and graded for&amp;nbsp;most recommendations (see the &quot;Major Recommendations&quot; field).&lt;/p&gt;&lt;/div&gt;" />
    </Field>
  </Section>
  <Section SecID="427" OrdBy="700" Name="Benefits/Harms of Implementing the Guideline Recommendations">
    <Field FieldID="152" OrdBy="705" ID="428" Name="Potential Benefits" Type="text">
      <FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The risk stratification algorithm in the original guideline document may help identify patients at high risk for venous thromboembolism (VTE) and decrease unnecessary prophylaxis measures in low risk patients. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;VTE prophylaxis may prevent a life threatening event (pulmonary embolism) as well as chronic post-thrombotic syndrome. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" />
    </Field>
    <Field FieldID="153" OrdBy="710" ID="429" Name="Potential Harms" Type="text">
      <FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Adverse event rates of sequential compression device (SCD) are low and generally minor. They include discomfort/intolerance and skin abrasions. Discomfort may lead to decreased adherence. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Risk assessment is easily obtained from a patient's history and therefore is non-invasive. It could be harmful if done incorrectly. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Subcutaneous injections are painful for patients and required a skilled provider for administration. Appropriate mechanical prophylaxis requires patient and nurse effort. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Pharmacologic prophylaxis carries a significant risk of bleeding. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" />
    </Field>
  </Section>
  <Section SecID="430" OrdBy="800" Name="Contraindications">
    <Field FieldID="144" OrdBy="805" ID="431" Name="Contraindications" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Contraindications to Mechanical Prophylaxis&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Deep vein thrombosis (DVT), suspected or existing (can use graduated compression stockings) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Extremity to be used has acute fracture &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Extremity to be used has peripheral intravenous (PIV) access &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Skin conditions affecting extremity (e.g., dermatitis, burn) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Unable to achieve correct fit due to patient size &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Contraindications to Pharmacologic Prophylaxis&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Absolute Contraindications&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Bleeding disorder, known or tendency &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Hemorrhage, evidence of or high risk of &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Platelet count unable to be sustained &amp;gt;50,000/mm&lt;sup&gt;3&lt;/sup&gt; &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Relative Contraindications&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Intracranial mass &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Lumbar puncture or epidural catheter removal in prior 12 hours &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Neurosurgical procedure &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Pelvic fracture within past 48 hours &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Uncontrolled hypertension &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" />
    </Field>
  </Section>
  <Section SecID="432" OrdBy="900" Name="Qualifying Statements">
    <Field FieldID="137" OrdBy="905" ID="433" Name="Qualifying Statements" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This Best Evidence Statement addresses only key points of care for the target population; it is not intended to be a comprehensive practice guideline. These recommendations result from review of literature and practices current at the time of their formulation. This Best Evidence Statement does not preclude using care modalities proven efficacious in studies published subsequent to the current revision of this document. This document is not intended to impose standards of care preventing selective variances from the recommendations to meet the specific and unique requirements of individual patients. Adherence to this Statement is voluntary. The clinician in light of the individual circumstances presented by the patient must make the ultimate judgment regarding the priority of any specific procedure.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
  </Section>
  <Section SecID="434" OrdBy="1000" Name="Implementation of the Guideline">
    <Field FieldID="131" OrdBy="1010" ID="436" Name="Description of Implementation Strategy" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Applicability and Feasibility Issues&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;There is evidence that venous thromboembolism (VTE) events are increasing in the pediatric population, and it has become evident to many providers, including medical and surgical specialists, that health care providers must do a better job of prevention. These care recommendations provide a means to assess patients at risk and mitigate that risk in the safest possible way. As the recommendations are newly developed, the feasibility of implementation has as yet been untested. Generally, the team believes implementation efforts will need to address:&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Education and training of staff to perform the risk assessment and review of contraindications, and to order prophylaxis &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Identifying an appropriate time and place during the hospitalization to apply the recommendations &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Ensuring adequate equipment and supplies &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Successfully achieving patient and family buy-in &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;A tool in the electronic health record (EHR) may need to be developed to improve reliable use of the recommendations.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="117" OrdBy="1015" ID="437" Name="Implementation Tools" Type="picklist-many">
      <FieldValue Value="Audit Criteria/Indicators" />
      <FieldValue Value="Clinical Algorithm" />
    </Field>
  </Section>
  <Section SecID="439" OrdBy="1100" Name="Institute of Medicine (IOM) National Healthcare Quality Report Categories">
    <Field FieldID="50" OrdBy="1105" ID="440" Name="IOM Care Need" Type="picklist-many">
      <FieldValue Value="Staying Healthy" />
    </Field>
    <Field FieldID="51" OrdBy="1110" ID="441" Name="IOM Domain" Type="picklist-many">
      <FieldValue Value="Effectiveness" />
      <FieldValue Value="Patient-centeredness" />
    </Field>
  </Section>
  <Section SecID="442" OrdBy="1200" Name="Identifying Information and Availability">
    <Field FieldID="97" OrdBy="1201" ID="392" Name="Bibliographic Source(s)" Type="citation">
      <FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Cincinnati Children's Hospital Medical Center. Best evidence statement (BESt). Venous thromboembolism (VTE) prophylaxis in children and adolescents. Cincinnati (OH): Cincinnati Children's Hospital Medical Center; 2014 Feb 18. 14 p.  [40 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" />
    </Field>
    <Field FieldID="124" OrdBy="1205" ID="443" Name="Adaptation" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable: The guideline was not adapted from another source.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="128" OrdBy="1215" ID="445" Name="Date Released" Type="text">
      <FieldValue Value="2014 Feb 18" />
    </Field>
    <Field FieldID="158" OrdBy="1225" ID="447" Name="Guideline Developer(s)" Type="orglist-p">
      <FieldValue Value="Cincinnati Children's Hospital Medical Center - Hospital/Medical Center" />
    </Field>
    <Field FieldID="125" OrdBy="1235" ID="449" Name="Source(s) of Funding" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Cincinnati Children's Hospital Medical Center&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="126" OrdBy="1240" ID="450" Name="Guideline Committee" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Multidisciplinary Venous Thromboembolism (VTE) Prophylaxis Best Evidence Statement (BESt) Team&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="127" OrdBy="1245" ID="451" Name="Composition of Group That Authored the Guideline" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;em&gt;Leader/Co-Author&lt;/em&gt;: Erin Shaughnessy, MD, Pediatric Hospital Medicine&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Co-Authors&lt;/em&gt;: Katie Meier, MD, Pediatric Hospital Medicine; Eloise Clark, MPH, MBA, Methodologist&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Contributors&lt;/em&gt;: Cristina Tarango, MD, Pediatric Hematology; Ranjit Chima, MD, Pediatric Critical Care; Rebeccah Brown, MD, Pediatric Surgery; Jaime Rice Denning, MD, Pediatric Orthopaedic Surgery; Joel Sorger, MD, Pediatric Orthopaedic Surgery&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="147" OrdBy="1250" ID="452" Name="Financial Disclosures/Conflicts of Interest" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Conflict of interest declaration forms are filed with the Cincinnati Children's Hospital Medical Center (CCHMC) Evidence-Based Decision Making (EBDM) group. No financial or intellectual conflicts of interest were found.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="120" OrdBy="1256" ID="393" Name="Guideline Status" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="118" OrdBy="1260" ID="454" Name="Guideline Availability" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Available from the &lt;a href=&quot;https://www.cincinnatichildrens.org/service/j/anderson-center/evidence-based-care/recommendations/topic&quot; title=&quot;Cincinnati Children's Hospital Medical Web site&quot;&gt;Cincinnati Children's Hospital Medical Web site&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="119" OrdBy="1265" ID="455" Name="Availability of Companion Documents" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The following are available:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Judging the strength of a recommendation. Cincinnati (OH): Cincinnati Children's Hospital Medical Center; 2008 Jan. 1 p. Available from the &lt;a href=&quot;https://www.cincinnatichildrens.org/-/media/cincinnati%20childrens/home/service/j/anderson-center/evidence-based-care/legend/judgingrecommendationstrength%20717.pdf?la=en&quot; title=&quot;Cincinnati Children's Hospital Medical Center&quot;&gt;Cincinnati Children's Hospital Medical Center&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Grading a body of evidence to answer a clinical question. Cincinnati (OH): Cincinnati Children's Hospital Medical Center; 1 p. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Table of evidence levels. Cincinnati (OH): Cincinnati Children's Hospital Medical Center; 2008 Feb 29. 1 p. Available from the &lt;a href=&quot;https://www.cincinnatichildrens.org/-/media/cincinnati%20childrens/home/service/j/anderson-center/evidence-based-care/legend/table%20of%20evidence%20levels%20-%20legend.pdf?la=en&quot; title=&quot;Cincinnati Children's Hospital Medical Center&quot;&gt;Cincinnati Children's Hospital Medical Center&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;In addition, suggested process or outcome measures are available in the &lt;a href=&quot;https://www.cincinnatichildrens.org/service/j/anderson-center/evidence-based-care/recommendations/topic&quot; title=&quot;Cincinnati Children's Hospital Medical Center (CCHMC) Web site&quot;&gt;original guideline document&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="143" OrdBy="1275" ID="457" Name="Patient Resources" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None available&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="142" OrdBy="1280" ID="458" Name="NGC Status" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary was completed by ECRI Institute on June 18, 2014.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="141" OrdBy="1290" ID="460" Name="Copyright Statement" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary is based on the original full-text guideline, which is subject to the following copyright restrictions:&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Copies of this Cincinnati Children's Hospital Medical Center (CCHMC) Best Evidence Statement (BESt) are available online and may be distributed by any organization for the global purpose of improving child health outcomes. Examples of approved uses of the BESt include the following:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Copies may be provided to anyone involved in the organization's process for developing and implementing evidence based care. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Hyperlinks to the CCHMC Web site may be placed on the organization's Web site. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The BESt may be adopted or adapted for use within the organization, provided that CCHMC receives appropriate attribution on all written or electronic documents. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Copies may be provided to patients and the clinicians who manage their care. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;Notification of CCHMC at &lt;a href=&quot;mailto:EBDMInfo@cchmc.org&quot;&gt;EBDMInfo@cchmc.org&lt;/a&gt; for any BESt adopted, adapted, implemented or hyperlinked by the organization is appreciated.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
  </Section>
  <Section SecID="99999" OrdBy="99999" Name="Disclaimer">
    <Field FieldID="99999" OrdBy="99999" ID="99999" Name="NGC Disclaimer" Type="text">
      <FieldValue Value="&lt;p&gt;The National Guideline Clearinghouseâ¢ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the &lt;a href=&quot;/help-and-about/summaries/inclusion-criteria&quot;&gt;NGC Inclusion Criteria&lt;/a&gt;.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Readers with questions regarding guideline content are directed to contact the guideline developer.&lt;/p&gt;" />
    </Field>
  </Section>
</Version>